Patent US4330557A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4330557A Expired / Lapsed US ⏱️ 0.0 years remaining

Acyl-carnitine and use thereof in parenteral administration of triglycerides

Assignee: Individual
•
Filing: 1980-03-17
•
Granted: 1982-05-18
•
Expires: 2000-03-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A composition for total or supplemental parenteral nutrition of patients in need thereof for the treatment of shock and trauma is disclosed. The composition comprises a therapeutically effective amount of triglycerides and an amount of an acyl-carnitine, typically acetyl-carnitine, or a pharmaceutically acceptable salt thereof sufficient to increase free fatty acid oxidation.

Inventors

  • 👤 Claudio Cavazza

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 18:10
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K31/22

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 97 words
In the method of increasing in a human the level of fatty acids selected from the group consisting of oleic acid, linoleic acid, palmitic acid, stearic acid and linolenic acid by parenteral intravenous administration of one or more triglycerides of said fatty acid to a human, the improvement which comprises sumultaneously administering a quantity of an acyl-carnitine sufficient to enhance the oxidation of said fatty acids in the body of said human, said acyl-carnitine having the general formula ##STR3## wherein R represents acetyl, propionyl, butyryl, hydroxy butyryl, hexanoyl, octanoyl, decanoyl, palmitoyl, stearoyl, acetoacetyl, succinyl, isovaleryl and crotonyl.
Claim 2
Dependent Claim 97 words
In the method of increasing in a human the level of fatty acids selected from the group consisting of oleic acid, linoleic acid, palmitic acid, stearic acid and linolenic acid by parenteral intravenous administration of one or more triglycerides of said fatty acid to a human, the improvement which comprises sumultaneously administering a quantity of an acyl-carnitine sufficient to enhance the oxidation of said fatty acids in the body of said human, said acyl-carnitine having the general formula ##STR3## wherein R represents acetyl, propionyl, butyryl, hydroxy butyryl, hexanoyl, octanoyl, decanoyl, palmitoyl, stearoyl, acetoacetyl, succinyl, isovaleryl and crotonyl.
Claim 3
Independent Claim 78 words
A method of treating patients in need of total parenteral nutrition, which comprises parenterally administering to a patient in need thereof an amount of physiologically acceptable triglycerides therapeutically effective for nourishing said patient and in combination therewith an amount of an acyl-carnitine of the general formula: ##STR4## wherein R represents acetyl, propionyl, butyryl, hydroxy butyryl, hexanoyl, octanoyl, decanoyl, palmitoyl, stearoyl, acetoacetyl, succinyl, isovaleryl and crotonyl or a pharmaceutically acceptable salt thereof sufficient to increase free fatty acid oxidation.
Claim 4
Independent Claim 78 words
A method of treating patients in need of total parenteral nutrition, which comprises parenterally administering to a patient in need thereof an amount of physiologically acceptable triglycerides therapeutically effective for nourishing said patient and in combination therewith an amount of an acyl-carnitine of the general formula: ##STR4## wherein R represents acetyl, propionyl, butyryl, hydroxy butyryl, hexanoyl, octanoyl, decanoyl, palmitoyl, stearoyl, acetoacetyl, succinyl, isovaleryl and crotonyl or a pharmaceutically acceptable salt thereof sufficient to increase free fatty acid oxidation.
Claim 5
Dependent Claim 12 words
The method according to claim 1, wherein said acyl-carnitine is an L-acyl-carnitine.
Claim 6
Dependent Claim 41 words
The method according to claim 1, which further comprises orally or parenterally administering daily for 12 to 24 hours after discontinuation of said triglyceride administration, from about 30 mg to about 200 mg of said acyl-carnitine per kg of body weight.
Claim 7
Dependent Claim 118 words
A parenterally administerable aqueous intravenous pharmaceutical composition for increasing in the body of a human recipient thereof the level of fatty acids selected from the group consisting of oleic acid, linoleic acid, palmitic acid, stearic acid and linolenic acid, said composition comprising a quantity of one or more triglycerides of said fatty acids sufficient upon hydrolysis in the body to afford a nutritionally effective amount of said fatty acid, and an amount of an acyl-carnitine or a pharmaceutically acceptable salt thereof sufficient to enhance the oxidation of said fatty acids in the body, said acyl-carnitine having the general formula ##STR5## wherein R represents acetyl, propionyl, butyryl, hydroxy butyryl, hexanoyl, octanoyl, decanoyl, palmitoyl, stearoyl, acetoacetyl, succinyl, isovaleryl and crotony.
Claim 8
Dependent Claim 118 words
A parenterally administerable aqueous intravenous pharmaceutical composition for increasing in the body of a human recipient thereof the level of fatty acids selected from the group consisting of oleic acid, linoleic acid, palmitic acid, stearic acid and linolenic acid, said composition comprising a quantity of one or more triglycerides of said fatty acids sufficient upon hydrolysis in the body to afford a nutritionally effective amount of said fatty acid, and an amount of an acyl-carnitine or a pharmaceutically acceptable salt thereof sufficient to enhance the oxidation of said fatty acids in the body, said acyl-carnitine having the general formula ##STR5## wherein R represents acetyl, propionyl, butyryl, hydroxy butyryl, hexanoyl, octanoyl, decanoyl, palmitoyl, stearoyl, acetoacetyl, succinyl, isovaleryl and crotony.
Claim 9
Dependent Claim 24 words
The composition according to claim 5, wherein said amount of acyl-carnitine or pharmaceutically acceptable salt thereof is from about 2 to about 30 g/l.
Claim 10
Dependent Claim 47 words
The composition according to claim 5 comprising: ______________________________________ soybean oil 50-200 g/l glycerine 22-26 g/l egg yolk phospolipids (ovolecithin) 10.5-12.5 g/l acetyl-carnitine or a pharmaceutically acceptable salt thereof 5-25 g/l sodium hydroxide sufficient to adjust pH of composition to 5.5-9.0 distilled water balance to 1 liter. ______________________________________
Claim 11
Dependent Claim 37 words
The composition according to claim 5, comprising: ______________________________________ cottonseed oil 100-200 g/l soybean lecithin 10-30 g/l sorbitol 40-60 g/l D,L-α-tocopherol 0.5-1 g/l acetyl-carnitine or pharmaceutically acceptable salt thereof 5-25 g/l distilled water balance to 1 liter. ______________________________________
Claim 12
Dependent Claim 34 words
The composition according to claim 5, comprising ______________________________________ sesame oil 100-200 g/l glycerine 20-30 g/l cetylstearylsulfonic acid 1-1.5 g/l propionyl-carnitine or pharmaceutically acceptable salt thereof 3-20 g/l distilled water balance to 1 liter ______________________________________
Claim 13
Dependent Claim 36 words
The composition according to claim 5, comprising: ______________________________________ safflower oil 100-200 g/l sorbitol 50-70 g/l polysorbate 8-12 g/l D,L-α-tocopherol 0.5-1 g/l acetoacetyl-carnitine or pharmaceutically acceptable salt thereof 2-20 g/l distilled water balance to 1 liter ______________________________________
Claim 14
Dependent Claim 11 words
The composition according to claim 5, wherein said acyl-carnitine is L-acyl-carnitine.
Claim 15
Dependent Claim 11 words
The composition according to claim 7, wherein said acetyl-carnitine is L-acetyl-carnitine.
Claim 16
Dependent Claim 11 words
The composition according to claim 8, wherein said acetyl-carnitine is L-acetyl-carnitine.
Claim 17
Dependent Claim 11 words
The composition according to claim 2, wherein said propionyl-carnitine is L-propionyl-carnitine.

References Cited (Backward Citations)

US3793450A Cited
US3810994A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-05-17 1985-11-16 1986-05-18 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-05-17 1989-11-16 1990-05-18 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-05-17 1993-11-16 1994-05-18 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag